Publications

Publications for Ganesh Raj, M.D., Ph.D.

The dilemma of a rising prostate-specific antigen level after local therapy: what are our options? Zaorsky NG,Raj GV,Trabulsi EJ,Lin J, Den RB. Semin Oncol. 2013 Jun;40(3):322-36. doi: 10.1053/j.seminoncol.2013.04.011.

Ex vivo culture of human prostate tissue and drug development. Centenera MM, Raj GV, Knudsen KE, Tilley WD, Butler LM. Nat Rev Urol. 2013 Jun 11. doi: 10.1038/nrurol.2013.126. [Epub ahead of print]

Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer. Ravindranathan P, Lee TK, Yang L, Centenera MM, Butler L, Tilley WD, Hsieh JT, Ahn JM, Raj GV. Nat Commun. 2013;4:1923. doi: 10.1038/ncomms2912.

Dual roles of PARP-1 promote cancer growth and progression. Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, Dean JL, Liu F, Planck JL, Ravindranathan P, Chinnaiyan AM, McCue P, Gomella LG, Raj GV, Dicker AP, Brody JR, Pascal JM, Centenera MM, Butler LM, Tilley WD, Feng FY, Knudsen KE. Cancer Discov. 2012 Dec;2(12):1134-49. doi: 10.1158/2159-8290.CD-12-0120. Epub 2012 Sep 19.

Paxillin mediates extranuclear and intranuclear signaling in prostate cancer proliferation. Sen A, De Castro I, Defranco DB, Deng FM, Melamed J, Kapur P, Raj GV, Rossi R, Hammes SR. J Clin Invest. 2012 Jul 2;122(7):2469-81. doi: 10.1172/JCI62044. Epub 2012 Jun 11.

Management of biochemical recurrence after primary localized therapy for prostate cancer. Darwish OM, Raj GV. Front Oncol. 2012;2:48. doi: 10.3389/fonc.2012.00048. Epub 2012 May 23.

Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Centenera MM, Gillis JL, Hanson AR, Jindal S, Taylor RA, Risbridger GP, Sutherland PD, Scher HI, Raj GV, Knudsen KE, Yeadon T; Australian Prostate Cancer BioResource, Tilley WD, Butler LM. Clin Cancer Res. 2012 Jul 1;18(13):3562-70. doi: 10.1158/1078-0432.CCR-12-0782. Epub 2012 May 9.

Central role for PELP1 in nonandrogenic activation of the androgen receptor in prostate cancer. Yang L, Ravindranathan P, Ramanan M, Kapur P, Hammes SR, Hsieh JT, Raj GV. Mol Endocrinol. 2012 Apr;26(4):550-61. doi: 10.1210/me.2011-1101. Epub 2012 Mar 8.

Significance of PELP1 in ER-negative breast cancer metastasis. Roy S, Chakravarty D, Cortez V, De Mukhopadhyay K, Bandyopadhyay A, Ahn JM, Raj GV, Tekmal RR, Sun L, Vadlamudi RK. Mol Cancer Res. 2012 Jan;10(1):25-33. doi: 10.1158/1541-7786.MCR-11-0456. Epub 2011 Nov 15. PMID: 22086908 [PubMed - indexed for MEDLINE]

Evidence of epithelial to mesenchymal transition associated with increased tumorigenic potential in an immortalized normal prostate epithelial cell line. Marian CO, Yang L, Zou YS, Gore C, Pong RC, Shay JW, Kabbani W, Hsieh JT, Raj GV. Prostate. 2011 May;71(6):626-36. doi: 10.1002/pros.21278. Epub 2010 Oct 13.

Paxillin regulates androgen- and epidermal growth factor-induced MAPK signaling and cell proliferation in prostate cancer cells. Sen A, O'Malley K, Wang Z, Raj GV, Defranco DB, Hammes SR. J Biol Chem. 2010 Sep 10;285(37):28787-95. doi: 10.1074/jbc.M110.134064. Epub 2010 Jul 13.